AVEO Pharmaceuticals (AVEO) Receiving Somewhat Favorable Media Coverage, Report Finds
Press coverage about AVEO Pharmaceuticals (NASDAQ:AVEO) has been trending somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AVEO Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.0712588932028 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- AVEO Pharmaceuticals, Inc. (AVEO) has a value of $3.51 per share While Blackhawk Network Holdings, Inc. (HAWK) is … – Stocks Gallery (stocksgallery.com)
- Here Are Two Ways To Play The AVEO Pharmaceuticals, Inc … – Insider Financial (insiderfinancial.com)
- Andreas Athanasiou Could Ditch Red Wings For KHL (techkenyot.com)
- Colorectal Cancer – Pipeline Review, H1 2017; New Report Launched (sbwire.com)
- Nasopharyngeal Cancer Pipeline Medical Survey Reports & Reviews 2017 (medgadget.com)
Shares of AVEO Pharmaceuticals (AVEO) traded up 6.57% during trading on Friday, hitting $3.73. 5,470,551 shares of the company were exchanged. The firm’s market capitalization is $441.29 million. AVEO Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $3.82. The firm’s 50-day moving average price is $2.79 and its 200 day moving average price is $1.32.
A number of research analysts recently weighed in on AVEO shares. FBR & Co restated an “outperform” rating and set a $3.00 price objective on shares of AVEO Pharmaceuticals in a research report on Monday, May 22nd. Zacks Investment Research raised shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 23rd. ValuEngine cut shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Piper Jaffray Companies reaffirmed a “positive” rating on shares of AVEO Pharmaceuticals in a report on Friday, June 23rd. Finally, BidaskClub raised shares of AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 16th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company. AVEO Pharmaceuticals has a consensus rating of “Buy” and an average price target of $3.08.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Stock Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.